SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
NEW YORK, Dec. 03, 2015 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has commenced in the United States District Court for the District of Maryland against Osiris Therapeutics, Inc. (“Osiris” or the “Company”) (Nasdaq:OSIR) on behalf all persons or entities who purchased Osiris securities between May 12, 2014 and November 20, 2015, inclusive (the “Class Period”).
Shareholders who incurred losses on shares purchased within the Class Period are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774.
If you purchased the shares of Osiris Therapeutics, Inc., you may, no later than January 22, 2016, request that the Court appoint you lead plaintiff of the proposed class.
On November 16, 2015, the Company surprised investors by disclosing that it had “determined to correct the revenue recognition for three contracts which will result in a decrease in product revenues of $1.8 million in the first quarter of 2015, a decrease in product revenue of $1.0 million in the second quarter, an increase in product revenues of $0.8 million in the third quarter of 2015 and a decrease in product revenues of $1.1 million in 2014.”
Following this news of an accounting restatement, Osiris shares fell, dropping $3.02, or 21.53%, to close at $10.97 on November 17, 2015.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com. All e-mail correspondence should make reference to the “Osiris Investigation.”
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
Contact: Wolf Haldenstein Adler Freeman & Herz LLP Patrick Donovan, Esq. Gregory Stone, Director of Case and Financial Analysis Email: [email protected], [email protected] or [email protected] Tel: (800) 575-0735 or (212) 545-4774
